Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy

Phase 2

Terminated

Conditions: Osteosarcoma
Sarcoma

Interventions: Device: Microwave ablation
Device: Cryoablation
Device: Radiofrequency ablation
Other: BPI-Short form
Other: FACT-G7

Registration Number: NCT01986829

Lead Sponsor: Washington University School of Medicine

Brief Summary: This phase II trial studies how well cryoablation, radiofrequency ablation, or microwave ablation works in treating patients with metastatic sarcoma stable on chemotherapy. Cryoablation kills tumor cells by freezing them. Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Microwave ablation kills tumor cells by heating them to several degrees above body temperature.

Detailed Description: Not available

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 9

Inclusion Criteria

Histologically or cytologically confirmed high-grade metastatic sarcoma that has been stable on 6-12 cycles of one chemotherapeutic regimen (cytotoxic or biologic) although a change in chemotherapy is allowed if it is a result of toxicity/tolerability rather than progression. A patient must not have evidence of progression at any time while on chemotherapy in order to be eligible for this trial.
Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥10 mm with CT scan, PET CT, or MRI exam.
At least 18 years of age.
ECOG performance status ≤ 2 (Karnofsky ≥60%)
Normal bone marrow and organ function as defined below:
- Leukocytes ≥ 3,000/mcL
- Absolute neutrophil count ≥ 1,500/mcl
- Platelets ≥ 100,000/mcl
- Total bilirubin ≤ 1.5 x IULN or 3x IULN with normal ALT and AST in patients with Gilbert's disease
- AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN
- Creatinine less than the institutional upper limit of normal OR creatinine clearance ≥ 50 mL/min/1.73 m2
- INR<1.5 or patient off Coumadin at the time of ablation
No more than 10 treatable lesions as evaluated by an experienced interventional oncologic radiologist for eligibility and lesion accessibility as the ablation of more than 10 lesions becomes technically infeasible. These lesions must be treated in a two- to three-week time period from initial interventional radiology evaluation. Lung and liver lesions can range from 1 cm to 7 cm for a single lesion and no greater than 5 cm for multiple lesions. There are no size criteria for the osseous lesions.
The lesions will be amenable to a safe, ultrasound/computed tomographic/fluoroscopic guided percutaneous approach. The targeted metastases must be sufficiently separable from the central nervous system, major peripheral motor nerves, bowel, and bladder. All lesions must be amenable to treatment.
If patients have received radiation therapy, there must be a one-month washout period.
Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of ablation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
Patient (or legally authorized representative if applicable) must be able to understand and willing to sign an IRB approved written informed consent document.

Exclusion Criteria

History of other malignancy ≤ 5 years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only, carcinoma in situ of the cervix, or localized prostate cancer.
Receiving any other investigational agents simultaneously or within 3 weeks following ablation procedure.
Known brain metastases. Patients with known brain metastases must be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
Intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant and/or breastfeeding.
Patients whose treatment plans include continuing chemotherapy after ablation as per the treating physician, as ablation therapy is meant to serve as maintenance therapy in lieu of chemotherapy.

Exclusion Criteria

Not provided

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (ablation)	BPI-Short form	* Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion. * Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)
Treatment (ablation)	Microwave ablation	* Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion. * Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)
Treatment (ablation)	Cryoablation	* Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion. * Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)
Treatment (ablation)	FACT-G7	* Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion. * Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)
Treatment (ablation)	Radiofrequency ablation	* Patients undergo cryoablation, radiofrequency ablation, or microwave ablation of each lesion. * Patients complete pain survey (BPI-Short form) and quality of life questionnaires (FACT-G7)

Primary Outcome Measures

Name	Time	Method
Progression-free Rate	3 months	Defined as the percentage of patients with no progression (local recurrence of an ablated lesion or the appearance of a new lesion) after ablation.

Secondary Outcome Measures

Name	Time	Method
Change in Quality of Life (QOL) Following Ablation Procedure as Measured by the Participant's Worry That the Condition Will Get Worse	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	* Measured with the FACT-G7 validated survey. Final assessment at time of disease progression. * The question participant was asked was "I worry that my condition will get worse" * 7 questions about quality of life with answers that range from 0=not at all to 4 = very much * Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean QOL scores between any two times. All analyses will be two-sided at a significance level of 0.05. This statistical analysis was not able to be performed due to the sample size being too small.
Change in Quality of Life (QOL) Following Ablation Procedure as Measured by the Participant's Nausea	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	* Measured with the FACT-G7 validated survey. Final assessment at time of disease progression. * The question participant was asked was "I have nausea" * 7 questions about quality of life with answers that range from 0=not at all to 4 = very much * Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean QOL scores between any two times. All analyses will be two-sided at a significance level of 0.05. This statistical analysis was not able to be performed due to the sample size being too small.
Overall Survival (OS)	Assessed up to 5 years	-Defined as time from diagnosis of metastatic disease to the time of death
Change in Quality of Life (QOL) Following Ablation Procedure as Measured by the Participant's Lack of Energy	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	* Measured with the FACT-G7 validated survey. Final assessment at time of disease progression. * The question participant was asked was "I have a lack of energy" * 7 questions about quality of life with answers that range from 0=not at all to 4 = very much * Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean QOL scores between any two times. All analyses will be two-sided at a significance level of 0.05. This statistical analysis was not able to be performed due to the sample size being too small.
Change in Quality of Life (QOL) Following Ablation Procedure as Measured by the Ability of the Participant to Enjoy Life	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	* Measured with the FACT-G7 validated survey. Final assessment at time of disease progression. * The question participant was asked was "I am able to enjoy life" * 7 questions about quality of life with answers that range from 0=not at all to 4 = very much * Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean QOL scores between any two times. All analyses will be two-sided at a significance level of 0.05. This statistical analysis was not able to be performed due to the sample size being too small.
Change in Quality of Life (QOL) Following Ablation Procedure as Measured by the Ability of the Participant to Sleep Well	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	* Measured with the FACT-G7 validated survey. Final assessment at time of disease progression. * The question participant was asked was "I am sleeping well" * 7 questions about quality of life with answers that range from 0=not at all to 4 = very much * Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean QOL scores between any two times. All analyses will be two-sided at a significance level of 0.05. This statistical analysis was not able to be performed due to the sample size being too small.
Change in Quality of Life (QOL) Following Ablation Procedure as Measured by the Contentment of the Participant's Qualify of Life	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	* Measured with the FACT-G7 validated survey. Final assessment at time of disease progression. * The question participant was asked was "I am content with the quality of my life right now" * 7 questions about quality of life with answers that range from 0=not at all to 4 = very much * Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean QOL scores between any two times. All analyses will be two-sided at a significance level of 0.05. This statistical analysis was not able to be performed due to the sample size being too small.
Change in Quality of Life (QOL) Following Ablation Procedure as Measured by the Participant's Pain	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	* Measured with the FACT-G7 validated survey. Final assessment at time of disease progression. * The question participant was asked was "I have pain" * 7 questions about quality of life with answers that range from 0=not at all to 4 = very much * Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean QOL scores between any two times. All analyses will be two-sided at a significance level of 0.05. This statistical analysis was not able to be performed due to the sample size being too small.
Change in Pain Following Ablation Procedure	Pre-treatment (baseline), post-treatment (1-month post ablation), and disease progression (up to 5 years post-ablation)	Measured using the Brief Pain Inventory. Final assessment at time of disease progression. Generalized estimating equation (GEE) analysis will be used to take into account the correlation of repeated measures from the same subject. Contrast statements will be used to compare mean BPI scores between any two times. All analyses will be two-sided at a significance level of 0.05.

Trial Locations

Locations (1): Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States

Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy

Recruitment & Eligibility

Study & Design

Trial Locations

Instant Trial Alerts

Instant Trial Alerts